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license (http://creativeautosomal dominant early-onset AD (EOAD), gene discovery in familial EOAD camemore or less to
a standstill. Only 5%of EOADpatients are carrying a pathogenic mutation in one of the AD genes or a
apolipoprotein E (APOE) risk allele ε4, most of EOAD patients remain unexplained. Here, we aimed
at summarizing the current knowledge of EOAD genetics and its role in ongoing approaches to under-
stand the biology of AD and disease symptomatology as well as developing new therapeutics. Next,
we explored the possible molecular mechanisms that might underlie the missing genetic etiology of
EOAD and discussed how the use of massive parallel sequencing technologies triggered novel gene
discoveries. To conclude, we commented on the relevance of reinvestigating EOAD patients as a
means to explore potential new avenues for translational research and therapeutic discoveries.
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The term dementia is used to define a heterogeneous
group of progressive and degenerative brain pathologies,
clinically characterized by deterioration in memory,
learning, orientation, language, comprehension, and judg-
ment. AD (OMIM# 104300), in its typical clinical presenta-
tion with progressive loss of memory and disturbance of
additional cognitive functions namely word-finding, spatial
cognition, reasoning, judgment, and problem solving [1],
is the leading cause of dementia in the elderly. Of all demen-
tia patients, 50% to 75% present with AD, which affects
between 23 and 35 million people worldwide [2]. Age is
the most prominent biological risk factor [3], and the age
of 65 years is often used to classify AD patients in early-
onset (EOAD) and late-onset (LOAD) groups. Of all AD pa-
tients, around 10% are diagnosed with EOAD [4], and they
present with their first symptoms between 30 and 65 yearsthor. Tel.: 132 3 265 1101; Fax 132 3 265 1113.
ristine.vanbroeckhoven@molgen.vib-ua.be
16/j.jalz.2016.01.012
e Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).with most of the EOAD patients being diagnosed between
45 and 60 years. Besides the typical clinical presentation
with memory impairment, atypical clinical presentation
with focal cortical symptoms, for example, visual dysfunc-
tion, apraxia, dyscalculia, fluent and non-fluent aphasia,
executive dysfunction, has also been reported. This atypical
presentation is more frequently reported in EOAD patients
compared to LOAD, who mostly present with typical mem-
ory phenotype [5]. Additionally, a nonmemory phenotype is
seen in roughly 25% of EOAD patients in whom visual or
apraxic and language phenotypes are more frequent [5].
The neuropathologic hallmarks of AD brains are extra-
cellular accumulation of diffuse and neuritic amyloid
plaques, composed of amyloid-b (Ab) peptide, and
frequently surrounded by dystrophic neurites and the intra-
neuronal accumulation of neurofibrillary tangles (NFTs)
composed of hyperphosphorylated protein tau (p-tau)
[6,7]. These pathologic features are accompanied by
gliosis and the loss of neurons and synapses [7]. Although,
some studies reported a larger neuropathologic burden [8]
or a more widespread pathology extending outside the
medial temporal lobe in younger patients [5], overall theimer’s Association. This is an open access article under the CC BY-NC-ND
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largely similar, indicating that at the end-stage of disease,
it is difficult to distinguish the two AD age groups by
any other criterion than onset age.
The main incentive for this review was the recent
renewed interest in EOAD genetic studies due to the
availability of high-throughput, genome-sequencing and
exome-sequencing technologies, and bioinformatic tools,
permitting new attempts to unravel the missing genetic etiol-
ogy of EOAD. The expectations are that these new genetic
approaches will uncover new molecular pathways or new
molecular components of already known pathways. Further-
more, the availability of new genetic markers will help
refining the different genetic signatures of clinical AD, al-
lowing a more accurate stratification of patient cohorts, pre-
clinical and clinical, for medical research, and for clinical
trials. In the long term, the ability to identify different under-
lying molecular pathologies of clinical AD patients or at risk
individuals will pave the way for personalized medicine and
health care.2. The genetic etiology of EOAD
In contrast to LOAD which is a complex disorder with a
heterogeneous etiology and an heritability of 70 to 80%
[9,10], EOAD is an almost entirely genetically determined
disease with a heritability ranging between 92% to 100%
[9]. Between 35 to 60% of EOAD patients have at least
one affected first-degree relative [11–13], and in 10% to
15% of those familial EOAD patients, the mode of
inheritance is autosomal dominant transmission [11,13].
Genetic analysis of exceptionally large and informative
monogenic pedigrees was the basis for the identification of
high-penetrant mutations in the three EOAD genes, coding
for the amyloid precursor protein (APP) and the presenilins
1 and 2 (PSEN1 and PSEN2).2.1. Identification of causal EOAD genes in extended
pedigrees
Down syndrome (DS), caused by chromosome 21 (par-
tial) trisomy, played a pivotal role in the early attempts to
identify genes for inherited EOAD. DS patients were shown
to present with a comparable brain pathology of amyloid
plaques and tau tangles as AD patients [14]. The strong
homology between the amyloid b (Ab) protein peptides, iso-
lated from vessels [15] and from plaques [16] from DS and
AD brains, was a first indication that both diseases shared a
common genetic mechanism associated with chromosome
21 [15,17]. Whole-genome-linkage (WGL) studies in AD
families provided supporting evidence for a genetic defect
located on chromosome 21q [18–20]. Cloning of the gene
coding for the amyloid b precursor protein (APP) [21],
from which the amyloid b peptides are produced, and its
mapping to chromosome 21q21.2–21q21.3 [22,23],
encouraged a series of genetic studies aiming atidentifying mutations in AD patients and families. Initial
genetic studies in large families with autosomal dominant
AD were negative [24,25] but could be explained by the
observation of a high degree of genetic heterogeneity in
familial AD indicating that genes other than APP had to
be involved [26].
A segregation study in extended multigenerational fam-
ilies with autosomal dominant cerebral hemorrhage with
amyloidosis Dutch type (HCHWA-D), conclusively linked
APP to the disease [27]. HCHWA-D brain pathology con-
sists mainly of vascular amyloid depositions of the same
Ab observed in AD brains [28]. Sequencing identified a
mutation affecting the Ab sequence in patients with
HCHWA-D [29] and segregated with disease [30]. The dis-
covery of a APP mutation linked to vascular Ab pathology
in HCHWA-D encouraged new mutation studies of APP
in AD families. A first mutation was identified confirming
a direct role for APP in AD pathogenesis in some AD
families [31].
Segregation studies in EOAD pedigrees, negative for
APP mutations, led to the identification of a new locus for
EOAD on chromosome 14q24.3 [32–35]. Genetic mapping
and gene cloning followed by mutation screening of
candidate genes [36–38] identified presenilin 1 (PSEN1) as
an EOAD gene with at that time unknown functions [39].
Based on protein homology, a second presenilin protein
was identified and mapped to chromosome 1q31–q42
[40,41], in the region that was linked to AD in a series of
families known as descendants of Volga-Germans [42,43]
and was named presenilin 2 (PSEN2).2.2. Genetic and phenotypic heterogeneity in EOAD
To date, 52 pathogenic mutations in APP have been re-
ported in 119 probands of autosomal dominant families
(http://www.molgen.vib-ua.be/ADMutations) [44]. Most
of the APP mutations are nonsynonymous within or
flanking the Ab sequence (Fig. 1A). However, 25 genomic
duplications of variable size containing APP have been
identified co-segregating with AD in as many autosomal
dominant families, as reported in http://www.molgen.
vib-ua.be/ADMutations [44] and reviewed in [45],
mimicking partial trisomy 21. Furthermore, a recessive
one amino acid deletion (p.E693D) [46] and a recessive
missense mutation with dominant negative effect on amy-
loidogenesis (p.A673V) [47,48] were described (Table 1).
Missense mutations are identified at least 4-folds more
frequently than APP genomic duplications in AD patients.
Disease onset of APP mutation carriers ranged between 45
and 60 years [49,50]. In contrast to the missense mutations,
showing a near-complete disease penetrance, APP genomic
duplications display reduced penetrance and higher vari-
ability in onset age [45]. Besides the pathogenic mutations,
a rare protective variant p.A673T in APP was reported that
was enriched in the Icelandic population [51]. At the same
amino acid position, the p.A673V variant showed
Fig. 1. APP protein mutations and structure. (A) APP protein sequence from amino acid residue 647 to 730 is presented, sequence in green depicts the extra-
cellular domain, in orange the transmembrane domain and in dark blue the intracellular domain. Known pathogenic mutations are reported in purple and, if
available, the mutation alias is shown, genomic duplications are not represented in the figure. In red are the two recessive pathogenic mutations, in gray the
nonpathogenic mutations. A circle encloses the residue p.A673 because the change to T is described as protective against AD as well the change to V in
the heterozygous state. An equal (5) marks a nonpathogenic silent mutation at residue p.G708. A delta (D) indicates a deletion. The cleavage sites of a, b,
andg secretases are markedwith black dotted lines. (B) Schematic presentation of the APP proteolytic processes. The nonamyloidogenic and the amyloidogenic
pathways are illustrated. For clarity, a general g-secretase cleavage site is reported.
R. Cacace et al. / Alzheimer’s & Dementia 12 (2016) 733-748 735antiamyloidogenic properties when identified in the
heterozygous state [47], suggestive of a protective effect
(Fig. 1A).
Of all three EOAD genes, PSEN1 is most frequently
mutated with 215 mutations (Fig. 2A) in 475 probands
(http://www.molgen.vib-ua.be/ADMutations) [44]. InPSEN2,
31 mutations have been identified, 15 pathogenic in 24 pro-
bands and 16 with pathogenicity nature unclear (Fig. 2B).
The mutation spectrum of the PSEN genes includes missense
mutations, small insertions, and deletions (indels) as well as
genomic deletions specifically in PSEN1, which lead to in-
frame exon 9 skipping (http://www.molgen.vib-ua.be/
ADMutations) [44] (Table 1). The onset age of carriers of a
PSEN1mutation ranged from 30 to 50 years. PSEN2mutationTable 1
Genetic heterogeneity in Alzheimer’s disease (AD): Known causal early-onset AD
Gene Chromosome Inheritance Gene iden
APP 21q21.1–21q21.3 Autosomal dominant
Autosomal recessive
Protective
Linkage a
PSEN1 14q24.3 Autosomal dominant
de novo
Linkage a
PSEN2 1q31–q42 Autosomal dominant Linkage a
*The total number of APP mutations includes two causal recessive mutations.carriers have generally a wider onset age range from 40 to
70 years [49,50]. With a few exceptions, disease penetrance
is complete for PSEN1mutations [50]. In case of PSEN2mu-
tations, disease penetrance is more difficult to establish
because far less families have been reported and the onset
age range is much wider [50]. PSENmutations are commonly
inherited in an autosomal dominant manner, but de novo mu-
tations in PSEN1 have been described in EOAD patients with
disease onset as early as 28 years [52,53].
Two families have been described that segregate domi-
nant EOAD mutations in a homozygous state, a Italian fam-
ily with the APP mutation p.A713T [54] and a Colombian
family with the PSEN1mutation p.E280A [55]. In both fam-
ilies, the homozygous carriers did not seem to be moregene
tification Mutation spectrum Mutations (N)
nalysis Missense
Gene Duplication
Amino acid deletion
54*
nalysis Missense
Small indels
Genomic deletions
215
nd homology mapping Missense 31
Fig. 2. PSENs protein mutations and structure. (A) PSEN1 and (B) PSEN2 protein sequences. In blue are marked the cytoplasmic domains, in yellow the trans-
membrane domains, in red the luminal domains, and in green the one intermembrane/IX transmembrane domain. Pathogenic or predicted pathogenic mutations
are in purple. In orange are mutations with unclear pathogenicity and in gray are reported nonpathogenic mutations. Different nucleotide variants which lead to
the same amino acid change, are reported only once. A delta (D) indicates deletions. An asterisk (*) marks two aspartates (D), which are the catalytic amino acids
located in transmembrane domain VI (PSEN1 is D257 and PSEN2 is D263) and in transmembrane domain VII (PSEN1 is D385 and PSEN2 is D366). Arabic
numbers indicate the last amino acid residue of every topological domain based on Uniprot database (PSEN1 P49768 and PSEN2 P49810). (C) Schematic pre-
sentation of APP and PSEN complexes. For PSENs, alternative predicted protein conformations are shown. The region with variable topology is framed in
dotted line and includes either an intermembrane domain with intracellular C-terminus or a ninth transmembrane domain with extracellular C-terminus.
The black dots on the transmembrane domains indicate the catalytic aspartates location. APP is inserted between PSENs transmembrane domains VI and
VII. The a, b, and g secretases cleavage sites are schematically indicated.
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findings is that the homozygous state of autosomal
dominant mutations in AD is not lethal as initially
hypothesized. This may also suggest the possible presence
of additional protective genetic factors, which may modify
the disease presentation.
In an EOAD patient cohort, the estimated mutation fre-
quencies for the three genes were ,1% for APP, 6% for
PSEN1, and 1% for PSEN2 [56]. Together, they explain
only 5%–10% of EOAD patients [9,56], whereas
depending on the study, 23% to 88.2% of autosomal
dominant patients remain genetically unexplained
[9,11,57–59] (Fig. 3). The wide divergences in unexplained
EOAD patients and families might result from differences in
study design or sampling biases. Besides the genetic hetero-
geneity, phenotypic heterogeneity is also reported in EOAD.
This complicates the clinical diagnosis in younger patients.
Atypical presentation with language impairment was re-
ported for specific PSEN1 mutations [49,50]. Prominentbehavioral symptoms (also presenting symptoms) like
delusion, hallucinations, and apathy, are described for a
subset of PSEN1 and PSEN2 mutations [49,50]. In some
cases, the clinical symptoms fulfilled the criteria for a
diagnosis of frontotemporal dementia, for example, in the
case of the PSEN1 mutation p.G183V. In this specific
example, the autoptic pathologic and immuno-
histochemistry analysis of the brain showed pick-type tauop-
athy, normally caused by MAPT mutations, in absence of
extracellular Ab deposits [60]. The neurologic symptom of
myoclonus is present in most of monogenic EOAD patients
and increases with the disease duration; seizures were also
reported as presenting symptom for some PSEN1 mutations
and are very common in APP duplication carriers (including
Down syndrome patients) [49,50]. Extrapyramidal
symptoms are not uncommon in PSEN1 mutations carriers
but very rare for PSEN2 and APP and tend to appear after
several years into the disease course [49,50]. Spastic
paraparesis has been associated with specific PSEN1
Fig. 3. Missing genetic etiology of early-onset Alzheimer’s disease (EOAD). The pie charts indicate the distribution of EOAD and late-onset Alzheimer’s dis-
ease (LOAD) patients (dark blue), the fraction of sporadic and familial EOAD patients with the sub-fraction of autosomal dominant patients (light emerald). The
orange pie chart depicts the fraction of unexplained autosomal dominant families. The possible mechanisms that may explain the missing genetic etiology of
EOAD are divided in two groups arising from the red pie chart: (1) possible undetected genetic alterations due to different causes, listed arising from the red pie
chart (right side) and (2) possible undetected epigenetic dysregulation (left side). For both scenarios, some examples of study designs (e.g., family based,
extreme trait design and so forth or investigation of DNA(de) methylation and so forth) and technological approaches such as next-generation sequencing
(NGS), chromatin immunoprecipitation assay combined with sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq) are schematically suggested.
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plaques without a dense core or neuritic dystrophy (“cotton
wool plaques”) is reported in the frontal cortex of the
patients presenting the phenotype [61]. Cerebellar ataxia is
a rare event but is present for specific PSEN1 mutations,
like in the case of the p.S170F mutation co-segregating
with a Cathepsin D variant, suggesting a deleterious
epistatic effect on the disease course [62]. Taken together,
this indicates that it is reasonable to continue efforts to
both unravel the genetic etiology of EOAD and to search
for modifier of the phenotype in presence of known patho-
genic mutations.2.3. APOE in EOAD
A genome-wide linkage study in families with LOAD and
subsequent association studies in patient/control cohortsTable 2
Risk variants and genetic modifiers in EOAD
Gene Variant Effect on EOAD
PSEN1 Promoter SNVs Increased risk
APOE ε4 allele Increase risk–highest in the
ε2 allele Delays AAO
CCL11 p.A23T Delays AAO
PRNP p.M129V Increased risk–VV homozyg
Octapeptide repeat insertions Earlier AAO
SORL1 Nonsynonymous rare variants Increased risk–signal driven
Abbreviations: EOAD, early-onset Alzheimer’s disease; SNVs, single nucleotididentified the ε4 allele of the apolipoprotein E gene
(APOE) as a major genetic risk factor for LOAD [63–65].
The presence of one or two copies of the APOE ε4 allele
increased the risk to develop LOAD by a factor 3 up to
15-fold in a dose-dependent manner [66,67].
The APOE ε4 allele also increased risk for EOAD in car-
riers of at least one ε4 allele and was highest in those with a
positive family history (Table 2) [12]. In carriers, the homo-
zygosity for the APOE ε4 allele was sufficient to signifi-
cantly increase risk for EOAD independent of other
genetic factors. In contrast, in carriers, heterozygous for
the APOE ε4 allele risk was only significantly increased in
the presence of a positive family history of disease, indi-
cating that the presence of one ε4 allele was insufficient to
increase risk for AD before the age of 65 years. It also sug-
gested that the APOE ε4 allele may modify the expression
of other genetic factors contributing to disease. However,References
[68,69]
presence of positive family history–and earlier AAO [12,70,71]
[70–73]
[74]
osity and highest in presence of positive family history [75]
[76]
by positive family history [77]
e variants; AAO, age-at-onset.
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APOE as both carriers and noncarriers of a ε4 allele have an
increased risk in the presence of a positive family history.
Contrary to the risk-increasing effect of the APOE ε4 allele,
it was demonstrated that the ε2 allele exerted a protective ef-
fect [72,73]. Different from the mutations in APP, PSEN1,
and PSEN2, the APOE ε4 allele was considered neither
necessary nor sufficient to cause AD. However, this
concept might need to be reconsidered based on a more
recent study [78], which showed that the effect of APOE
on AD risk is comparable to the effect of a major genetic fac-
tor with semidominant inheritance [78].
Analysis of the APOE genotypes in families segregating
dominant APP (p.V717I) [79], PSEN1 (p.E280A) [70], or
PSEN2 (p.N141I) mutations, showed that onset age
decreased in presence of the ε4 allele in mutation carriers,
whereas those with the ε2 allele had later onset ages
[70,71]. A larger study of samples of the PSEN1
(p.E280A) family [73] confirmed the APOE ε4 allele as an
age-at-onset (AAO) modifier (w12 years of delay)
compared to the ε4 allele (Table 2) [73]. Nevertheless, these
APOE genotype effects were not observed in all families
with a pathogenic mutation [90]. Genome-wide searches in
the Volga German families (PSEN2 p.N141I) identified at
least three additional genetic loci (1q23.3, 17p13.2, and
7q33) [91], which could harbor modifier genes. Further-
more, a whole genome-sequencing approach of a large Co-
lombian kindred (PSEN1 p.E280A), detected a protective
variant (p.A23T, rs1129844) in the gene CCL11 encoding
eotaxin-1 that delayed onset age of AD by a decade [74].
Autosomal dominant families, segregating mutations in
one of the 3 causal EOAD genes, show often variability in
clinical presentation, even in the presence of the same muta-
tion. A meta-analysis study showed that the phenotypic het-
erogeneity could be partially explained by the mutated gene,
the type of mutation, and the family history. But, this is
not always the case, indicating that in certain families, addi-
tional modifier factors (i.e., gene-gene and gene-
environment interactions) may be involved [90].Table 3
Genetic heterogeneity in AD: Neurodegenerative brain diseases genes
presenting with AD-like phenotype
Gene Chromosome
Typical
phenotype
Mutation
frequency
in AD (%) References
GRN 17q21.31 FTLD ,2% [80–82]
MAPT 17q21.31 FTLD ,1% [83,84]
C9orf72 9p21.2 FTLD ,1% [85–87]
PRNP 20p13 Prion disease ,1% [88,89]3. The amyloid cascade
APP and its processed peptides are the cornerstone of the
“amyloid cascade hypothesis” [92]. This hypothesis states
that the accumulation of Ab is the causative agent of AD
by destroying the synapses, inducing the formation of
NFTs, and ultimately inducing neuronal loss [92]. Two
distinct and mutually exclusive pathways cleave APP
(Fig. 1B). In one pathway, the cleavage by a-secretase and
g-secretase produces three fragments: a secreted C-terminal
fragment (sAPPa), p3, and the APP intracellular domain
(AICD; Fig. 1B). In the second, and thus amyloidogenic
pathway, APP is cleaved by the b-secretase (beta-site APP
cleaving enzyme 1, BACE1), followed by g-secretase cleav-
age. The cleavage by b-secretase generates a large soluble
extracellular secreted domain (sAPPb). The remainingmembrane bound APP fragment, C99, is processed by mul-
tiple g-secretase cleavages. The first occurs at the cleavage
site epsilon (ε-site, Fig. 1B) to produce the AICD and
then, after g-secretase cleavages trim the membrane bound
producing Ab species that differ in protein length including
Ab38, Ab40 (most common fragment), Ab42 (self-aggrega-
tive fragment), and Ab43 [93]. Genetic mutations in APP are
located in or near the Ab sequence and in the proximity of
the cleavage sites of the secretases (Fig. 1A), whereas
PSEN1 and PSEN2 mutations are scattered all over the pro-
tein (Fig. 2A and 2B). The mutations are predicted to cause
AD through aberrant APP processing determining either
increased Ab levels or increased production of Ab42 (and
Ab43) peptide over Ab40, triggering Ab aggregation [93].
From its postulation, the “amyloid cascade hypothesis” has
been supported and questioned (as reviewed by Morris
et al. [94]) acknowledging that Ab has an important role in
AD pathogenesis although its role in the disease process is
most likely much more multifaceted. This was corroborated
by the observation of a subgroup of clinically diagnosed AD
patients with neurodegeneration and cognitive deficits but
near absence of Ab deposits, defined as “suspected non-
AD pathology” (SNAP) [95]. In a clinical trial of anti-Ab
passive immunotherapy, 16.3% of the clinically diagnosed
AD patients had a negative-baseline amyloid positron emis-
sion tomography scan [96]. Studies on mild cognitive
impairment cohorts are ongoing to phenotypically classify
the SNAP patients [97,98], to better understand, if they
represent a subgroup of AD with pathologic features
independent from the amyloid cascade [99].4. The role of other neurodegenerative brain diseases
genes in EOAD expression
Possibly, some of the SNAP patients might be associated
with mutations in genes involved in other neurodegenerative
brain diseases (NBD). Mutations have been identified, at low
frequencies (less than 1%–2%), in genes causing frontotem-
poral lobar degeneration (FTLD), that is, mutations inMAPT
[83,84] and in granulin (GRN) [80–82], and the repeat
expansion in C9orf72 [85–87] (Table 3). The genetic hetero-
geneity of the phenotypic presentation of AD supports that
both diseases form part of an AD-FTLD disease continuum
[100,101]. An AD-like phenotype was also described in the
presence of a nonsense mutation in the prion protein
R. Cacace et al. / Alzheimer’s & Dementia 12 (2016) 733-748 739(PRNP p.Q160*) [88,89], gene responsible for inherited
neurodegenerative spongiform encephalopathies. Histopa-
thologic analysis of nonsense mutation carrier showed
neuritic plaque-like pathology and severe NTFs, the plaques
were immunonegative for Ab but immunopositive to PrP
leading to a pathological diagnosis of prion disease [88]
(Table 3). Moreover, a common coding polymorphism,
Methionine (M) to Valine (V) at position 129 of PRNP has
been associated with EOAD when identified in homozygous
state (MM and VV; Table 2) [75]. The risk was higher for the
VV and increased in patients with positive family history
[75]. In addition, increasing number of octapeptide repeat in-
sertions in PRNP have also been associated with younger
onset age in AD patients (Table 2) [76]. The genetic hetero-
geneity in some dementia patients leads to a later clinical
diagnosis and to flawed genetic testing. With the current
availability of massive parallel sequencing (MPS), causal
genes across NBD clinical diagnostic dementia subgroups
can be screened simultaneously, increasing the chances to
identify pathologic mutations independent of the clinical
diagnosis. It can be expected that the breadth and depth of
this etiological disease heterogeneity will be clarified more
fully in the coming years, as discussed in section 5 and 6.5. The role of EOAD genes in AD susceptibility
There is substantial evidence that apart from pathogenic
mutations, the EOAD genes also harbor genetic variations
that contribute to increased susceptibility for AD. For
example, single nucleotide variants (SNVs) in the promoter
region of APP or PSEN1 have been associated with
increased risk of LOAD [68,69,102]. Some APP promoter
SNVs, increase neuron-specific APP transcriptional activity
by near two-fold [103,104], and as such increase risk to
develop LOAD. PSEN1 promoter SNVs [68,69,102] could
alter protein expression in neurons [69,102] leading to
increased risk of both EOAD (Table 2) [68,69] and LOAD
[69]. Likewise, coding variants in the known causal genes
might influence AD risk; however, to date, there is little in-
formation available because causal EOAD genes are rarely
screened in LOAD patients [56,105]. Moreover, in EOAD
patients, the routine genetic testing paradigm was based on
mutation frequency (PSEN1 . APP . PSEN2) and
location of known mutations (exons 16 and 17 in APP
covering the Ab peptide cleavages sites) and was stopped
once a pathogenic mutation was identified.
Today, the availability of extended gene panels and MPS
technology, allows near unlimited screening of full coding
sequences of multiple disease genes in parallel across clin-
ical phenotypes ([105,106] and unpublished data).
Systematic screening of EOAD and LOAD patient cohorts
showed rare or novel mutations in causal AD genes in
LOAD patients ([105] and unpublished data) mutations in
APP outside the Ab coding exons and the occurrence in
one individual of mutations in more than one NBD genes
(unpublished data). This suggests that mutations in knownEOAD genes might act differently on disease expression,
which ranges from high penetrance (5 causal allele) and
early-onset age to low penetrance (5 risk allele) and late-
onset age, depending on the effect of the mutant allele on
protein function ([105] and unpublished data). The new chal-
lenge that we are facing when using these gene panels is the
high potential of identifying variants of uncertain signifi-
cance (VUSs). These VUSs lack supportive functional data
and can only be classified based on their likelihood of
pathogenicity using in silico information obtained using bio-
informatics prediction tools (e.g., predicting the impact of
the mutated amino acid residue on protein stability/function)
[107], data which are insufficient in a clinical diagnostic
setting.6. The missing genetics of EOAD
Rare high-penetrant mutations in APP, PSEN1, and
PSEN2 could explain only a small fraction of EOAD fam-
ilies, leaving a large group of autosomal dominant pedigrees
genetically unexplained [9,11,57–59] (Fig. 3). Additionally,
it was estimated that only between 5%–10% of EOAD [9,56]
can be explained by mutations in the three known EOAD
genes (Fig. 3). The limited number of resolved pedigrees
and large number of genetically unexplained EOAD
patients, indicated that additional causal genes remain to
be identified. Next generation sequencing technologies
(NGS), like whole-genome-sequencing (WGS) and whole-
exome-sequencing (WES), offered a next step to gain new
insights into the molecular genetic etiology of AD. Particu-
larly, these NGS technologies made it conceivable to recon-
sider those small families that had been excluded fromWGL
studies because of their limited genetic information content
and thus lack statistical power. Additionally, it became
possible to examine, in an unbiased manner, groups of unre-
lated AD patients selected for their extreme phenotypic char-
acteristics, for example, very early-onset age, familial
history of disease, or atypical clinical and/or neuropatholog-
ical phenotypes.
An early NGS study produced WES data of a clinically
diagnosed EOAD patient and identified in NOTCH3, a
known mutation that had been associated with cerebral
autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy [108], a dementia disorder that
shares clinical similarities with EOAD. The index patient
belonged to a consanguineous Turkish family with a com-
plex clinical history of neurologic and immunologic disor-
ders [108]. The study demonstrated that WES is a valid
tool to unravel the genetic etiology of complex diseases
[108]. A WES study in EOAD probands of autosomal
dominant families, who were negative for mutations in
the three EOAD genes, identified seven mutations on
screening of 29 probands (five missense and two nonsense
mutations) in the sorting protein-related receptor gene
(SORL1) [109]. Previous studies have shown reduced
expression of the SORL1 transcript in AD patients using
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the protein in APP and Ab trafficking [111]. One of the
EOAD missense mutations in SORL1 (p.G511R) that co-
segregates with autosomal dominant AD in one family
[109], is located within the VPS10P domain of SORL1.
This specific mutation was shown to reduce the capability
of the VPS10P domain to bind Ab, resulting in accumula-
tion of the peptide and lower turnover [112]. More, the
investigation of an EOAD patient-control cohort
confirmed the role of rare nonsynonymous coding variants
in SORL1 as risk factor for EOAD (Table 2), with the as-
sociation signal driven by familial patients [77]. Also,
both common and rare, noncoding and coding variants
in SORL1 have been associated with increased risk of
LOAD [113–115]. Three SORL1 coding mutations
(p.E270K and p.T947M, p.A528T) identified in a
family-based and cohort-based association study on
LOAD have been shown to increase Ab40 and/or Ab42
secretion when expressed in vitro [115]. These studies re-
inforced the role of rare variants in SORL1 in both EOAD
and LOAD risk. The screening of SORL1 in larger patient/
control groups will help defining the contribution of rare
genetic variants in SORL1 to AD etiology.6.1. Causal genes in unexplained EOAD families
Scarcity of sufficiently informative EOAD families, the
small number of family members available for genetic
analyses and the clinical and genetic heterogeneity, has
hampered WGL studies in identifying the actual underlying
gene defects [116]. An example is provided by the family-
based WGL study in the Swedish series, which includes
both EOAD and LOAD patients. The original WGL study
in multiple autosomal dominant families detected a sugges-
tive linkage at chromosome 5q35 [117]. The inclusion of
additional families to the WGL analysis did not confirm
the 5q35 locus [118], but the investigation of a selected num-
ber of families with autopsy confirmed AD revealed a sug-
gestive locus on chromosome 8q24 [119]. An independent
locus on chromosome 8q was identified in a Swedish family
in another WGL study [120]. In the aforementioned
examples, the underlying genetic defect has not yet been pin-
pointed. We also identified in one extended Dutch family, a
significant WGL peak at chromosome 7q36 but candidate
gene screening in this locus did not identify a mutation
that could explain the linkage [121].
Today, NGS technologies are used to examine unex-
plained EOAD families [122]. In large extended families,
the NGS approach can be preceded by a WGL analysis
to prioritize chromosomal regions that are more likely to
contain the disease gene. NGS data of two, distantly related,
patients can be sufficient to identify shared, protein
affecting, genetic variants in genes located in the linked
loci. An advantage of this combined approach of WGL
and NGS is a significant decrease in complexity of the
NGS data under analysis. Furthermore, the success rate ofthis approach can be substantially increased by including
additional family members both affected and/or unaffected.
The main strength of NGS technologies, however, is their
capability to identify putative disease genes by direct anal-
ysis of the data obtained of related family members
belonging to small nuclear families. Because of the familial
nature, these NGS studies are often limiting their first anal-
ysis to variants in coding sequences, particularly variants
predicted to have a high impact on the protein functioning
and thus identifying high-penetrant causal mutations. But
silent, noncoding and genomic variations can also exert an
effect on disease risk or causality. For example, the intron
4 variant (c.358–304 C. G) in SOD1 defines the activation
of a cryptic splice site with the inclusion of a pseudo-exon
leading to amyotrophic lateral sclerosis [123]. Also,
genomic duplications of the APP locus have been linked
to EOAD (as reviewed in section 2.2), and an inversion poly-
morphism comprising MAPT has been associated to
increased risk for neurodegenerative brain diseases like
progressive supranuclear palsy [124,125]. In case, a
candidate gene is identified in this NGS approach, the next
major step is to generate confirmatory evidence of its
pathogenic role in the disease. This can be obtained by co-
segregation studies of the putative disease causing mutation
in the family, by the screening of the candidate gene for mu-
tations in a patient cohort and its absence in a control cohort.
Limiting factors to the segregation analysis are the size of
the pedigree as well as the number of available samples.
Also, incomplete or age-dependent penetrance of the genetic
variants can complicate the interpretation of both the segre-
gation data as well as the presence of the variant in control
individuals.
Alternatively, an extreme trait design can be used to
sequence a small number of individuals at one or both ex-
tremes of the disease (endo) phenotype [126] as shown by
Nho et al. [127]. This approach, though it identified frequent
variants that may be associated with AD risk, provides
an example of using NGS with quantifiable traits as endo-
phenotype.6.2. Other mechanisms
In most of the EOAD families, the disease inheritance is
consistent with autosomal dominant transmission. Occa-
sionally, other transmission patterns were reported like
recessive mutations in APP [46,47] and de novo
mutations in PSEN1 [52,53] (described in section 2.2),
but they have not been systematically explored. A potential
study design to optimize their detection is the use of WGS
in small nuclear families or trios with neurologically
healthy parents and EOAD patients negative for the
APOE ε4 allele. It is possible to approach the data analysis,
based on the family history of disease, to identify either
recessive (positive family history) or de novo (negative
family history) mutations. In specific cases, that is, when
the family history is unknown, both hypotheses can be
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offspring can be used to define a genome-wide map of
runs of homozygosity (ROH), and these ROH regions can
be analyzed together with the WGS data of the parents to
identify recessive mutations. Recessive inheritance of AD
has already been examined before using either polymorphic
simple-tandem-repeat markers or high-density single
nucleotide polymorphism genotyping arrays, identifying
homozygous regions harboring potential candidate genes
[128–131]. Conversely, the WGS data can be analyzed
for de novo mutations present in the offspring but absent
in the parents. Limitations to these study designs are the
unavailability of both parents and, the possibility that
EOAD in the offspring resulted from a dominant
mutation that was undetected in the parent due to
incomplete penetrance or an AAO modifier. Alternative to
recessive or de novo mutations, sporadic EOAD patients
can also be explained by germline or somatic mosaicism
[132,133] as shown for the PSEN1 p.P436Q mutation
[132], with the degree of mosaicism affecting onset age
and clinical presentation. Also, epigenetic dysregulation
can affect gene expression in AD. Deoxyribonucleic acid
(DNA) (de)methylation, chromatin remodeling, and non-
coding RNAs (ncRNAs) expression could play a more im-
pacting role than initially thought in AD onset and
expression (Fig. 3). Alteration in methylation in the pro-
moter region of APP, PSEN1, and APOE have been
described in AD patients as well as histone acetylation
which was altered in both AD patients and in AD transgenic
mouse models (as reviewed by Lardenoije et al., [134]).
Imbalanced expression of noncoding RNAs, miRNA
particularly, has been identified in relation to AD (as re-
viewed by van den Hove et al. [135]). These mechanisms
affect gene expression without altering the DNA sequence
and are currently underinvestigated in EOAD patients. Two
epigenetic studies in LOAD [136,137], adopted novel
designs to control for confounding factors like the
different methylation pattern in different cells/tissues,
interindividual variability within the same tissue [138].
Both studies independently detected changes in methyl-
ation in four CpG sites close to ANK1, RPL13, CDH23,
and RHBDF2 [136,137]. This confirmed the respective
findings and supported the strength of the study designs.
Additionally, the recent availability of the epigenome
roadmap [139], a public data resource containing epige-
netic information from different cell types and tissues, is
paving theway to more comprehensive research. This effort
resulted, among others, in the identification of conserved
epigenomic signals at orthologous regions between mice
and humans, which upregulate the immune response genes
and downregulate the synaptic plasticity genes in the CK-
p25 mouse model of AD [140]. The major challenge of
this type of studies, in the years to come, will be to deter-
mine whether the epigenetic change is a cause or a conse-
quence of the disease and how the disease risk is
influenced by the alteration of the chromatin structure[141]. Moreover, it will be relevant to comprehend how
the epigenome signature varies between populations and
how the epigenetic findings will translate from mouse
models (e.g., CK-p25) to humans. The availability of epige-
nome data will allow the integration of genetic results
with epigenome regulation to better understand disease sig-
natures which may represent a potential target for future
diagnostic and treatment interventions.7. Translational research in autosomal dominant
families
On the one hand, the investigation of unexplained
EOAD families and patients aims at identifying novel
causal genes and pathways. On the other hand, an interna-
tional effort is ongoing to better understand the temporal
sequence and the earliest events, which lead to the endpoint
disease clinical manifestation. Longitudinal studies on
families segregating a monogenic form of AD and patients
with a known causal mutation are currently performed to
investigate the prodromal phase of the neurodegenerative
processes which ultimately lead to AD [142]. The under-
standing of the post-genomic consequences of the genetic
mutations aims at improving the AD diagnosis through
the identification of novel sensitive biomarkers (Box 1),
which correlate with earliest pathologic events and with
disease conversion and progression. This will also help in
the definition of targets for therapeutic screening and the
selection of uniform patients groups for targeted pharma-
ceutical approaches. Longitudinal studies in asymptomatic
mutation carriers have already demonstrated that at least
20 years before the clinical manifestation of cognitive def-
icits it is possible to detect the pathologic changes
happening in the brain using both biochemical and instru-
mental biomarkers (Box 1) [142,144]. The longitudinal
data investigation of cognitively unimpaired mutations
carriers from the Colombian PSEN1 kindred included in
the Alzheimer’s Prevention Initiative (API), for example,
led to the identification of a composite cognitive test
score that has improved power to detect preclinical AD
decline [150]. A direct application of this score could be
in identifying preclinical patients to include in prevention
trials [150]. In the API cohort, the anti-Abmonoclonal anti-
body crenezumab testing is ongoing [151]. Another
example of translational research is provided by the domi-
nantly inherited Alzheimer’s network trials unit, which is
currently testing in presymptomatic known mutation car-
riers two monoclonal anti-Ab antibodies (gantenerumab
and solanezumab) that target different Ab species [151].
Ab42-reducing approaches may have more efficacy in fa-
milial patients, because the increased production of Ab42
is caused by genetic mutations, in this way, it is possible
to attempt to increase the clearance of the toxic peptide
before the accumulation is too extensive. Taken together,
these examples demonstrate that families segregating a
monogenic form of AD and patients with a known causal
Box 1
Genetic, biochemical, neuroanatomic, and metabolic markers in
AD diagnosis
Genetic markers: APP, PSEN1, and PSEN2
APP (OMIM# 104760) contains 18 exons and spans a
genomic region of 6290 kb at chromosome
21q21.1–21q21.3. APP has several isoforms gener-
ated by alternative splicing. The APP770 is used as ca-
nonical isoform for mutation nomenclature.
Reference sequences are Gene NG_007376.1, cDNA
NM_000484.2, and Protein NP_000475.1. The Ab
protein is encoded by exons 16 and 17. APP is a
type I transmembrane protein (Fig. 1).
PSEN1 (OMIM# 104311) counts 13 exons and
spans 6 84 kb at chromosome 14q24.3. The first 4
exons contain untranslated sequence, and exons 1
and 2 represent alternate transcription initiation sites.
PSEN1 counts 467 amino acids residues. Reference se-
quences are Gene NG_007386.2, cDNANM_000021.
2, and protein NP_000012.1.
PSEN2 (OMIM# 600759) contains 12 exons and spans a
region of 625 kb at chromosome 1q42.13. The first
two exons encode the 5-prime untranslated region.
PSEN2 has 448 amino acids. Reference sequences are
Gene NG_007381.1, cDNA NM_000447.1, and pro-
tein NP_000438.1. The PSENs share an overall amino
acid homology of 67% and are multimeric protein pre-
dicted to cross the membrane 7–9 times (Fig. 2C).
Diagnostic molecular genetic screenings have been per-
formed so far by sequencing exon 16 and 17 (Ab coding
exons) of APP and all coding exons of PSEN1 and
PSEN2, after a decision paradigm based on gene muta-
tion frequencyPSEN1.APP.PSEN2. NGS technol-
ogies are sequencing in parallel the entire coding
sequence of all three causal genes either by gene-panels
approach [106] or by whole-exome sequencing [143].
Specific (or core) biochemical markers are Ab42, total
tau (t-tau), and phosphorylated tau (p-tau). These are
dosed in cerebrospinal fluid (CSF) on lumbar punc-
ture. These biomarkers are measured to provide a
reflection of the cerebral metabolic process of the pro-
tein transport between the brain and the CSF. General
consensus is that in AD patients, the CSF levels of
Ab42 are reduced, because of amyloid plaque forma-
tion in the brain, and that t-tau and p-tau are increased
because of neuronal cell loss [144,145]. Furthermore,
t-tau CSF levels increase with AD progression [145].
The better understanding of the pathologic processes
occurring in AD brains are triggering the validation of
novel CSF biomarkers (as reviewed in [146]) as the
APP-cleaving enzyme 1 (BACE1) levels, the dosage
of truncated amyloid-b isoforms, both linked to
amyloidogenesis and result increased in patients. APP
cleavage products, which are produced during APP
processing can be measured to assess drug efficacy.
F2-isoprostane a marker of mithocandrial dysfunction
as well as markers of synaptic degeneration (e.g.,
synaptotagmin, synapsin, synaptophysin and so forth)
and markers of brain injury (i.e., visinin-like protein 1
(VILIP-1) [147]), are under investigation to assess
their applicability in diagnostic.
Neuroanatomic markers such as computer-assisted to-
mography (CT) and volumetric magnetic resonance
imaging (MRI) are used to measure structural brain at-
rophy. Alteration in brain metabolic processed are
measured using metabolic markers, that is, positron-
emission tomography and single photon-emission
computed tomography (SPECT) with radiopharma-
ceutical agents, for example, fluorodeoxyglucose
(FDG). It is also possible to image in vivo amyloid
deposition, imaged by PETwith the use of Pittsburgh
compound B (PiB). A recent study shows that also tau
tangles correlate well with AD diagnosis, showing the
strongest predictive value for progression to AD
[148]. Although tau is a biomarker of brain injury,
synapse loss, and progression to neurodegeneration,
selective tau tracers for PET are not yet available
[149]. In vivo tau imaging will help in clarifying the
role of tau in AD onset and progression and will
support the clinical disease diagnosis [149].
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ical research. The knowledge of the molecular and cellular
biology of AD has already supported the development of
tools for disease diagnosis (Box 1), but efforts are still
ongoing to identify novel biomarkers for disease prediction
and prognosis. These will allow the selection of homoge-
neous cohorts of participants for clinical trials with a close
monitoring of the drug response.8. Lesson learned from research in LOAD
Locus heterogeneity and limitations in both pedigree size
and technologies were probably the major contributors to
the lack of additional genetic breakthroughs in EOAD.Mean-
while, the investigation of LOAD, using genome-wide associ-
ation studies (GWAS), led to the identification of common risk
variants within .20 genetic loci [114,152–156]. These
genetic loci could be grouped in three major biological
pathways: immune system; lipid metabolism; and synaptic
dysfunction/cell membrane processes (e.g., endocytosis)
[116,157,158]. Additionally, NGS resequencing efforts are
identifying rare variants (minor allele frequency ,1% in the
general population) with a strong effect on disease risk in
additional genes or in genes previously associated with
LOAD. Examples are provided by rare variants detected in
TREM2 [159,160] or ABCA7 [161,162]. Also, in these
cases, the main pathways involved are the immune response
(TREM2, ABCA7) and lipid metabolism (ABCA7) [157]. As
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the risk genes (e.g., TREM2 [163], ABCA7 [162], EPHA1
[164]) have been shown segregating in families, suggesting
a possible effect on disease penetrance, although further
studies are needed to strengthen this hypothesis. The role of
rare variants in EOAD has been less investigated nonetheless
a few examples are available like the rare protective variant
detected in APP [51] and the variant in CCL11 (eotaxin-1)
[74]. This last example is of particular relevance, as it demon-
strated an involvement of the immune pathway in modulating
the disease onset in presence of a highly penetrant mutation in
PSEN1. The molecular mechanism through which eotaxin-1
modulates AD onset needs further investigation but, if vali-
dated, may represent a first step to develop therapies able to
delay the onset of AD. This finding also supports the hypoth-
esis that rare variants canmodulate the disease onset andmost
likely also the disease progression. Taken together, the find-
ings suggest that Ab processing in LOAD could have a lesser
central role, whereas the clearance of the aggregates might be
involved in the disease pathogenesis [165].
On the one hand, the identification in EOAD of AAO dis-
ease modifiers (APOE: lipid metabolism and CCL11: im-
mune pathway) in genes belonging to two of the biological
pathways detected by GWAS in LOAD, is indicative of mul-
tiple (common) pathways modulating the clinical expression
of AD. On the other hand, the shared clinical features as well
as the pathologic findings in brain tissue of both EOAD and
LOAD suggest that discoveries obtained in EOAD will
likely translate to LOAD.9. Conclusions
The renewed interest in EOAD in the NGS era has the po-
tential to implement the knowledge of the molecular and
cellular mechanisms which ultimately lead to AD. The in-
depth genetic characterization, by systematic screening of
the dementia causal genes, will allow patient stratification
in more homogenous groups, leading to the selection of
unexplained EOAD, both familiar and sporadic patients to
include in further research. This can be gene hunting projects
or trials for biomarkers selection or compound testing,
paving the way to personalized medicine.
In parallel to the deep genetic profiling of patients cohorts,
the longitudinal follow-up of families with known mutations
will provide additional insights in the known disease process
that could have implications for diagnostics, for the develop-
ment of predictive tests, and for clinical trial design. In a
future prospective, the integration of NGS with data coming
from other–omics analysis (i.e., epigenomics, proteomics,
transcriptomics, and metabolomics), might lead to the identi-
fication of molecular disease signatures, identifying pat-
tern(s) of altered protein expression that are better able to
discriminate early disease stages and facilitate the identifica-
tion of novel causal proteins and pathways or to prioritize
genes and proteins as “druggable” molecular targets for
novel therapeutic approaches. In conclusion, tremendousprogresses have been made in the last years in disclosing
the pathologic mechanisms of AD. Novel regulatory mecha-
nism and biological pathways have been disclosed, but pre-
vention of the disease is still a challenge ahead. In this
review, we have summarized the main aspects of the research
in EOAD and how these have influenced the current knowl-
edge of the disease mechanisms. We suggest that continua-
tion of the investigations of families segregating known
mutations and the elucidation of the missing genetic etiology
in unexplained EOAD patients still has a vast potential to
deliver novel crucial pieces that will lead to a better under-
standing of the complex puzzle of AD at large.
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Fund, Belgium.RESEARCH IN CONTEXT
1. Systematic review: PubMed search, meeting ab-
stracts and presentations, were used to collect infor-
mation concerning Alzheimer’s disease (AD). The
search focus was on the genetics of early-onset AD
(EOAD), on the application of high-throughput
sequencing technologies and on ongoing trans-
lational studies on EOAD.
2. Interpretation: We provide a comprehensive review
on EOAD genetics. Despite the tremendous advance
in the field, a large part of the EOAD patients is still
unexplained. Thus, possible molecular mechanisms
that might underlie the missing genetic etiology of
EOAD are explored.
3. Future directions: The basis of the current knowledge
of AD is derived from genetic studies on large EOAD
pedigrees in the early 90s. Here, we suggest that the
use of high-throughput sequencing technologies
applied to EOAD patients has a vast potential
to deliver crucial information to help in better
understanding the molecular mechanisms of AD in
general.
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